Robert Kupor has joined Frazier & Company as a principal.Seattle-based Frazier & Company is a private merchantbanking firm specializing in advising and investing in healthcare and other high-growth situations. Kupor was abiotechnology analyst with Kidder, Peabody & Co. Formed in1991, Frazier & Company has advised and invested in severalhealth care companies, including Affymax N.V., InControl, CellGenesys, Tularik and NeoPath.

Carl E. Brooks was named president and chief executive ofCryopharm Corp., a privately held, development-stage companyspecializing in the long-term preservation of biologicallyimportant cells. Brooks was president of the Hyland Division ofBaxter International before joining Pasadena, Calif.-basedCryopharm.

Hector J. Gomez was named vice president of medical affairs atVertex Pharmaceuticals of Cambridge, Mass. He was vicepresident of clinical research at Immunomedics. Vertex(NASDAQ:VRTX) is using structure-based rational drug designto develop orally deliverable drugs.

CytoTherapeutics Inc. of Providence, R.I., appointed E. EdwardBaetge director of neuroscience. He was formerly leader of thecell and molecular neurobiology group at Bristol-Myers Squibb.CytoTherapeutics (NASDAQ:CTII) is developing therapeuticproducts to treat chronic diseases.

Collagen Corp. named Barry Calvarese director of regulatoryaffairs. He was director of scientific and regulatory affairs atAdvanced Surgical Intervention Inc. Collagen (NASDAQ:CGEN) ofPalo Alto, Calif., develops, manufactures and marketsbiomedical devices for treating defective, diseased, traumatizedor aging human tissues, and specialized catheter systems fortreating neurovascular disorders.

James T. O'Brien, former president and chief operating officerof Elan Corp. plc, was named the board of directors ofCarrington Laboratories Inc. The Irving, Texas, company(ASE:CRN) is focused on carbohydrate-based therapeutics fortreating major life-threatening illnesses and the dressing andmanagement of wounds.

Orville G. Kolterman, medical director of AmylinPharmaceuticals Inc., was named president of the Californiaaffiliate of the American Diabetes Association. Marjorie H.Tillman, Amylin's vice president and chief financial officer, wasnamed to the board of directors of the Diabetes Association'sSan Diego chapter. San Diego-based Amylin is focused ontherapeutic products based initially upon amylin, a newlydiscovered hormone that is believed to play a major role in theregulation of carbohydrate metabolism.

Genta Inc. (NASDAQ:GNTA) re-elected its eight members of theboard of directors. The company is developing pharmaceuticalproducts based on antisense technology.

(c) 1997 American Health Consultants. All rights reserved.